Your session is about to expire
← Back to Search
Creatine monohydrate for Depression
Phase 3
Waitlist Available
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-6 weeks
Awards & highlights
Study Summary
This trial will study whether adding creatine to electroconvulsive therapy (ECT) for major depressive disorder (MDD) helps the treatment work better, causes fewer side effects, and leads to a faster response.
Eligible Conditions
- Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3-6 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-6 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
HAMD-17
Secondary outcome measures
QIDS
Side effects data
From 2015 Phase 4 trial • 14 Patients • NCT0151463071%
Cold and flu symptoms
29%
Diarrhea
21%
Stomach Discomfort
14%
Muscle Cramps
7%
Lightheaded
7%
Numbness and Tingling in hands
7%
Headache
7%
Indigestion
7%
Polydipsia
7%
Swelling in Hands
7%
Nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Creatine Monohydrate
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Creatine monohydrateExperimental Treatment1 Intervention
Week 1: Creatine monohydrate 5g PO QID
Week 2 up to Week 6: Creatine monohydrate 5g PO qday
Group II: PlaceboPlacebo Group1 Intervention
Week 1: Placebo 5g PO QID
Week 2 up to Week 6: Placebo 5g PO qday
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Creatine monohydrate
2005
Completed Phase 4
~660
Find a Location
Who is running the clinical trial?
University of UtahLead Sponsor
1,104 Previous Clinical Trials
1,782,517 Total Patients Enrolled
23 Trials studying Depression
2,401 Patients Enrolled for Depression
Share this study with friends
Copy Link
Messenger